Skip to main content
. 2023 May 24;5(6):318–328. doi: 10.1002/acr2.11550

Figure 2.

Figure 2

Unadjusted health care costs (A) and adjusted cost differences (B) for the OCS‐initiator cohort exposure categories compared with the no‐OCS‐use cohort as the reference group (N = 27,352). aOther visits include ambulance, assisted living facilities, comprehensive rehabilitation facilities, custodial care facilities, hospice/home care services, intermediate care facilities, psychiatric facilities, and skilled nursing facilities. bOne patient with unknown sex in the OCS nonuser cohort was excluded from the adjusted analyses. c P < 0.01 for adjusted all‐cause total cost, medical cost (all categories), and pharmacy cost comparisons between each OCS use exposure category and the no‐OCS‐use cohort. d P = 0.22 for adjusted other medical cost comparison between patients in the no 6‐month periods of more than 5 mg/day OCS use exposure category and the no‐OCS‐use cohort. CI, confidence interval; OCS, oral corticosteroid; USD, United States dollars.